Barrett's Esophagus in Olmsted County

计划入组 60 人 · 首次发布于 2009 年 7 月 22 日

The Olmsted NAFLD Epidemiology Study (TONES)

计划入组 800 人 · 首次发布于 2020 年 4 月 28 日

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

计划入组 64 人 · 首次发布于 2025 年 7 月 29 日

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

OLMSTED MEDICAL CENTER

United States

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

Sol-Gel Completes Phase 3 Enrollment for Gorlin Syndrome Treatment SGT-610, Targets $300M Peak Revenue

Kamari Pharma Secures $23 Million Series A to Advance First-in-Class TRPV3 Inhibitor for Rare Genetic Skin Diseases

Orvida Pharma Reports Positive Phase 1a Safety Data for KM-023, First-in-Class TRPV3 Inhibitor for Olmsted Syndrome